OBJECTIVES: In 2014 the Catalan Health Service (CatSalut) published a guide (GAEIP)  which describes the methodology for the economic evaluation of medicines in Catalonia. Now the objective is to design the operational aspects to introduce both the economic evaluations (EE) and budget impact analyses (BIA) of medicines in the three Health Technology Assessment (HTA) programmes of CatSalut.  METHODS: The Commission for Economic Evaluation and Budget Impact (CAEIP) of CatSalut led the project that: 1) reviewed the processes undertaken by other countries that use EE/BIA of medicines; 2) ran focus groups with representatives of each of the three HTA programmes: primary and community care (PHF-APC), hospital medicines administered in ambulatory care (PHF-MHDA), and orphan medicines (PASFTAC); 3) validated the proposal through pilots in each programme. RESULTS: The project delivered a general framework to implement the EE and BIA in the current processes of each of the three HTA programmes, allowing them to fit it into their timings and particular needs. According to this proposal, companies will submit their EE and BIAs of medicines in a similar way to what they currently do in single technology appraisals. The HTA programmes will assess the quality of the submitted information, and may ask for additional analyses when required.  To date, the pilot on the therapeutic area of oncology has been completed (PHF-MHDA) whilst the other two are still ongoing. CAEIP also developed a set of formularies to be used by the companies when submitting the required information. Finally, the project was informative, as it highlighted the size the resources needed to implement this new process within the HTA programmes.  CONCLUSIONS: CatSalut continues with the deployment of EE and BIA as it believes both to be valuable when issuing recommendations on the use and the therapeutic positioning of medicines within the Catalan health system.